The FDA says abacavir (Ziagen) does not cause cardiovascular problems, opening the door for GSK to combine it with their new integrase inhibitor for naive patients

This will make it possible for GSK-ViiV to market their new Trii formulation of the new integrase inhibitor GSK572 (generic name: dolutegravir) plus Epzicom (abacavir plus epivir) as a once a day pill for naive patients

It contradicts all the previous studies that said that abacavir (Ziagen) causes increased cardiovascular risks.

http://www.aidsmap.com/page/1682771/

GSK is currently enrolling studies to get dolutegravir approved.  This drug may have activity against HIV with raltegravir resistance.  More on this soon.